News
First patient receives low-dose psilocybin in rare headache disorder trial
Oxford-headquartered Beckley Psytech has announced the first patient has been dosed in a ‘world-first’ clinical trial evaluating the effects of psilocybin for the treatment of short-lasting unilateral neuralgiform headache attacks (SUNHA).